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ABSTRACT
Introduction: The Cochrane Schizophrenia Group
(CSzG) has produced and maintained systematic
reviews of effects of interventions for schizophrenia
and related illness. Each review has a Plain Language
Summary (PLS), for those without specialised
knowledge, and an abstract, which are freely
available from The Cochrane Library (https://
summaries.cochrane.org). Increasingly, evidence is
being distributed using social media such as Twitter
and Weibo (in China) alongside traditional
publications.
Methods and analysis: In a prospective two-arm,
parallel, open randomised controlled trial with a 1:1
allocation ratio, we will allocate 170 published
systematic reviews into the intervention group
(tweeting arm/Weibo arm) versus the control group
(non-tweeting arm). Reviews will be stratified by
baseline access activity, defined as high (≥19 views
per week, n=14), medium (4.3 to 18.99 views per
week, n=72) or low (<4.3 views per week, n=84),
based on Google Analytics, which will also be used
for evaluating outcomes. The intervention group will
have three tweets daily using Hootsuite with a
slightly different accompanying text (written by CEA
and AB) and a shortened Uniform Resource Locator
(URL) to the PLS: a) The review title as it appears in
summaries.cochrane.org, b) A pertinent extract from
results or discussion sections of the abstract and c)
An intriguing question or pithy statement related to
the evidence in the abstract. The primary outcome
will be: total number of visits to a PLS in 7 days
following the tweet. Secondary outcomes will include
% new visits, bounce rate, pages per visit, visit
duration, page views, unique page views, time on
page, entrances, exiting behaviour and country
distribution.
Ethics and dissemination: This study does
not involve living participants, and uses
information available in the public domain.
Participants are published systematic reviews,
hence, no ethical approval is required. Dissemination
will be via Twitter, Weibo and traditional academic
means.
Trial registration number: ISRCTN84658943.
INTRODUCTION
For two decades, the Cochrane Schizophrenia
Group (CSzG) has been producing and main-
taining high quality systematic reviews and
meta-analyses of randomised controlled trials
evaluating the effects of interventions for
schizophrenia and related psychotic illnesses.
A systematic review “is a high-level overview of
primary research on a particular research
question that tries to identify, select, synthesize
and appraise all high quality research evidence
relevant to that question in order to answer
it,”1 and the well conducted ones tend to be
carried out by teams of experts. All published
versions of Cochrane systematic reviews and
protocols are available from the Cochrane
library (http://www.thecochranelibrary.com).
The full-text versions of these can be accessed
and downloaded freely (in some high-income
and most low-income countries) or at a cost to
Strengths and limitations of this study
▪ This is the first randomised controlled trial that
we are aware of to evaluate the impact of tweet-
ing health-related web links versus not tweeting
on access to the target webpage and/or related
webpages.
▪ This study will provide information to help quan-
tify the effects of tweeting evidence, and will
generate many questions for future research.
▪ Those interested in best evidence for people with
schizophrenia may be similar or different to
others interested in different areas of medicine,
however, in any given area of healthcare there
may be a critical mass of followers required to
gain traction in the wider community. We are
unable to estimate at this time, what the critical
number would be.
▪ We are using free-to-use software and may be
able to detect other meaningful effects using
more sophisticated tools, which are presently
inaccessible to us.
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others.2 Each review also has an award winning Plain
Language Summary (PLS) section to make it more access-
ible to people without specialised knowledge,3 and an
abstract, both of which are freely available from the
Cochrane PLS website (https://summaries.cochrane.org).
Twitter is a free to use social media platform that
allows users to send a 140-character message called a
‘tweet’. These tweets may contain ‘hashtags’ (#) and/or
a Twitter handle (@). # is the means to enable searching
for a topic and @ denotes a username for either a
person, a company or an entity. Presently, there are 284
million monthly active users sending out 500 million
tweets a day. Seventy-seven per cent of accounts are
outside the USA and 80% of tweets are sent from
mobile devices.4 Over the years, the use of Twitter in
healthcare has increased, encompassing issues relating
to public health surveillance, tracking disease activity of
the H1N1 pandemic and isolating the source of a
cholera outbreak in Haiti, among other tweets.5–7 The
promotion of systematic reviews via Twitter, however, is a
relatively recent development for most Cochrane Review
Groups,8 despite health-related Twitter messages com-
prising of a not so insigniﬁcant proportion of all Twitter
trafﬁc and even predicting geographic regions and
trends of illness, based on the tweets.9 The year 2011
marked the beginning of the CSzG using various social
media platforms and since early 2013, the CSzG invested
resources into use of social media as a way of raising
awareness of systematic reviews. Twitter, the most active
of platforms, is now frequently used by both the group
and its followers. The number of followers of the CSzG
on Twitter has risen from 296 (in March 2013) to 734
(as of 15 January 2015).
Although Twitter, Facebook and some other platforms
are not available in China, 91% of China’s population
use social media compared to about 67% of America’s.10
The CSzG has been working with a Chinese company,
Systematic Review Solutions Ltd,11 to disseminate paral-
lel messages on Weibo, a Twitter-like system, to their fol-
lowers, who currently number more than 6000. Weibo is
in the top 10 social media sites used in China, with over
600 million registered users, of which about 140 million
use it regularly (as of March 2014).12
Given the increasing use of social media and, in par-
ticular, Twitter, in healthcare, we propose to evaluate the
impact of tweeting a précis of CSzG’s systematic reviews
in a randomised controlled trial in most of the rest of
the world and mirroring this in China on Weibo. The
impact of this social media dissemination, however, is
unclear. As Twitter does not provide data to enable
assessment of impact, Google Analytics (GA) is an alter-
native source of data. GA is easy to use and has a wide
range of data accessible with the standard (free)
account.13
This trial aims to evaluate the impact of tweeting
health-related web links (freely available on summaries.
cochrane.org), versus not tweeting, on access to the
target webpage and/or related web pages.
METHODS AND ANALYSIS
Study design
Prospective two-arm, parallel, open randomised con-
trolled trial with a 1:1 allocation ratio as outlined below
in ﬁgure 1.
Eligibility criteria
Inclusion criteria
Published full text CSzG reviews in the Cochrane
Library and Plain Language. Summary (PLS) in sum-
maries.cochrane.org (N=170).
Exclusion criteria
Unpublished and withdrawn CSzG reviews.
Published protocol CSzG reviews that appear in The
Cochrane Library.
Any CSzG review not relevant to schizophrenia.
Randomisation
Cochrane Schizophrenia Group systematic review base-
line access activity was deﬁned as high (≥19 views per
week, n=14), medium (4.3 to 18.99 views per week,
n=72) or low (<4.3 views per week, n=84) based on GA
data for the period 21 September 2013 to 28 February
2014. This classiﬁcation was based on data exported
from GA on number of views within the pilot period
(about 3 months) and deciding on a suitable division
into categories based on a reasonable deﬁnition of high,
medium and low ‘popularity’, in terms of this data. This
categorisation was then checked by CEA and AAM to
ensure there was an even number of reviews within each
category in order to carry out the pairing. Reviews were
given a unique code, which, along with access activity
stratum, was supplied to one of the authors (AAM) who
performed the randomisation. Stratifying by baseline
access activity, and using a computer generated random
number sequence, reviews were ﬁrst allocated to Tweet
and non-Tweet arms, then into pairs of reviews that
would have the same reference period for outcome data
collection, then to day of the week (Tuesday, Wednesday
or Friday) and week number (1 to 29) that tweeting
would begin for reviews in the intervention arm. Finally,
the sequence of the three tweets for each review (the
tweet package) in the intervention arm was also
randomised.
Interventions
Intervention group
Reviews in the intervention group will be tweeted three
times on the same day at 10:30, 13:00 and 15:00 GMT as
guided by the SocialBro web tool, since there is some
evidence that multiple postings, three to four times a
day, of the same or similar tweet, can be useful for an
international following. Days for tweeting are prespeci-
ﬁed as Tuesday, Wednesday and Friday, as these are con-
sidered to have the heaviest trafﬁc.14 Each of the three
tweets has slightly different accompanying text:
2 Jayaram M, et al. BMJ Open 2015;5:e007695. doi:10.1136/bmjopen-2015-007695
Open Access
group.bmj.com on July 31, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
▸ The review title as it appears in summaries.cochrane.
org—and a shortened Uniform Resource Locator
(URL) to the PLS.
▸ A pertinent extract from the results or discussion sec-
tions of the abstract—and a shortened URL to the
PLS.
▸ An intriguing question or pithy statement directly related
to the evidence presented in the abstract—and a
shortened URL to the PLS.
An example of this is outlined in ﬁgure 2.
We are not testing the impact of the different types of
accompanying text. These have been formulated in
order to appeal to various followers of the CSzG Twitter
page and searchers. We are testing the impact of the
package of tweets. To assist the logistics of timing the
various tweets, we used Hootsuite, a social media man-
agement system. This free package allows formulation
and scheduling of tweets. Hootsuite is now available in
China and integrates with Weibo (http://blog.hootsuite.
com/chinese-localization-weibo/).
Control group
Reviews in the control group are those not tweeted by
the CSzG.
Figure 1 Flow diagram of the study. CSzG, Cochrane Schizophrenia Group; PLS, Plain Language Summary
Figure 2 Example of the three
tweets relating to the same
review.
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Outcomes and data collection
The primary outcome is the total number of visits to a
PLS in the 7 days following start of the tweeting
intervention. For reviews in the control arm, the
outcome period is the same within intervention–
control paired reviews. This includes all trafﬁc to
the PLS and trafﬁc directly from Twitter. The half-life
of a tweet (with a web link), deﬁned as “the amount
of time at which this link will receive half of the clicks
it will ever receive after it’s reached its peak”, has
been calculated as 2.8 h.15 However, to capture any
possible cascade effect of tweeting, we extend the
monitoring period to 7 days.16 Secondary outcomes
provide other measures of incoming activity (%
new visits, pages per visit, visit duration, page views,
unique page views, time on page, entrances, bounce
rate) and exiting behaviour (events, total events,
unique events).
In addition, we will report country distribution of
users clicking on PLSs in a separate table.
Table 1 Glossary of Google Analytic terms
Google term Explanation
Number of
clicks
Direct clicks traffic that does not originate from
search-engine results or a referring link in a
domain is identified as ‘direct’19
Visits Number of times people viewed the site
% New visits An estimate of the percentage of first time
visits
New visits Number of first-time visits (from people who
had never visited your site before)
Bounce rate Percentage of single-page visits (ie, visits in
which the person left the site from the
entrance page without interacting with the
page).
Pages/visit The average number of pages viewed during
a visit to the site. Repeated views of a single
page are counted (also called Average Page
Depth)
Average visit
duration
Average actual length of time a visitor spends
on the site.20 Google Analytics will record
visit duration for a maximum of 30 min, after
which it will time-out. If the tab is kept open
the duration will continue to be monitored
until this point21
All clicks the overview of all clicks onto the
website of interest19
Page views Number of pages viewed. Repeated views of
a single page are counted
Unique page
views
Number of visits during which the specified
page was viewed at least once. A unique
page view is counted for each page URL +
page Title combination
Average time
on page
Average amount of time visitors spend
viewing a specified page or set of pages
Entrances Number of times visitors entered your site
through a specified page or set of pages
Bounce rate Percentage of single-page visits (ie, visits in
which the person left the site from the
entrance page without interacting with the
page)
Twitter referrals clicks that originate from a
third-party website where a web link has been
provided to the page of interest21 22
Sessions Same as Unique page views
Page views Number of pages viewed. Repeated views of
a single page are counted.
Average
session
duration
Same as Average time on page (Only data
for the CSzG PLS pages will be recorded)
Outbound
clicks
Events An action tracked on the website—for
example, exit to Cochrane Library
Total events Total events is the number of times events
occurred
Unique events Unique events is the number of visits during
which one or more events occurred
URL, Uniform Resource Locator.
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Source of data
GA, originally called Urchin, before it was signed over to
Google in March 2005, will be used as data source for
outcomes. GA is mainly used by businesses to identify
customers’ needs and how those needs are being met.
With the production of various data reports in real-time,
GA can answer questions about who has visited, and
when and where they had visited, a site, as well as how
they ‘arrived’ at that site. GA is a good source of user-
relevant data accessible with the standard (free)
account.17 18 Table 1 outlines the glossary of GA terms.
Statistical considerations: power
The sample size for this study is ﬁxed by the number of
published Cochrane reviews under the jurisdiction
within the CSzG (n=170). Therefore, we can estimate
the magnitude of the detectable between-group differ-
ence in the primary outcome. With 5% two-sided α and
a sample size of 85 per arm, an effect size in the range
0.43–0.5 SDs is detectable with 80–90% power. This is
equivalent to a between-group difference in means of
2.8–3.3 visits per week.
Data analysis
We will compare characteristics of the reviews in the
intervention and control arms, including baseline access
activity, using appropriate descriptive statistics. The
primary between-group comparison will analyse reviews
as randomised, regardless of how much of the tweeting
intervention was actually employed, and will estimate the
difference in mean number of visits per week and 95%
CI, using analysis of covariance. This will be implemen-
ted using multivariable linear regression, and will
include in the model baseline number of visits and day
of the week that tweeting activity started. Secondary out-
comes will be analysed similarly.
As a secondary analysis of the primary outcome, we
will conduct a prespeciﬁed subgroup analysis to investi-
gate whether any effect of the intervention differs
according to baseline activity. We will do this by includ-
ing an appropriate interaction term in the primary
regression model.
We anticipate that the intervention will be implemen-
ted fully as planned, and that there will not be any
missing primary outcome data. However, in the event
that either of these assumptions is untrue, we will con-
sider sensitivity analyses to investigate the effect of the
receiving of the intervention as intended, and of imput-
ing missing outcome data.
ETHICS AND DISSEMINATION
This study does not involve any living participants and
uses information that is available in the public domain.
Participants in this study are systematic reviews rather
than people. The summaries.cochrane.org and The
Cochrane Library websites will be the participants, and
routine data will be extracted and recorded through GA.
As a result, no ethical approval is required.23 24 Results
will be disseminated via Twitter, Weibo and traditional
academic means.
Trial organisation
The trial is sponsored by the Nottinghamshire Mental
Health Trust. We have no support or clear reasons to
establish a Data Monitoring Committee or a Steering
Committee.
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